Navigation Links
Nile Therapeutics Reports 2011 Third Quarter Financial Results
Date:11/14/2011

escribed under the caption "Risk Factors" in Item 1A of its Annual Report on Form 10-K for the year ended December 31, 2010 filed with the Securities and Exchange Commission on March 14, 2011. Nile is providing this information as of the date of this press release and does not undertake any obligation to update any forward-looking statements as a result of new information, future events or otherwise.NILE THERAPEUTICS, INC.

(A DEVELOPMENT STAGE COMPANY)

CONDENSED STATEMENTS OF OPERATIONS

(unaudited)Three Months Ended September 30,Nine Months Ended September 30,2011201020112010IncomeCollaboration income$
813,000$
-$
,159,000$
-Operating expenses:Research and development1,470,0911,148,6412,795,3543,517,822General and administrative499,273664,0951,597,8551,732,745Total operating expenses1,969,3641,812,7364,393,2095,250,567Loss from operations(1,156,364)(1,812,736)(3,234,209)(5,250,567)Other income (expense):Interest income1,8805,9544,91217,526Interest expense----Other income (expense)10,411(2,711)8,901(2,793)Total other income (expense)

12,2913,24313,81314,733Net loss$
(1,144,073)$
(1,809,493)$
(3,220,396)$
(5,235,834)Basic and diluted loss per share$
(0.03)$
(0.05)$
(0.09)$
(0.17)Weighted-average common shares outstanding

39,707,76434,563,07336,526,34631,338,963NILE THERAPEUTICS, INC.

(A DEVELOPMENT STAGE COMPANY)

CONDENSED BALANCE SHEETSSeptember 30, 2011December 31, 2010(unaudited)ASSETS Current assets Cash and cash equivalents

$
2,607,336$
3,378,155Prepaid expenses and other current assets

420,653219,095Total current assets

3,027,9893,597,250 Property and equipment, net  

10,88616,765 Other noncurrent assets

51,93851,938Total assets

$
3,090,813$
3,665,953 LIABILITIES AND STOCKHOLDERS' EQUITY Current liabilities Accounts  payable

$
504,333$
332,380Accrued  expenses and other current liabilities
'/>"/>

SOURCE Nile Therapeutics, Inc.
Copyright©2010 PR Newswire.
All rights reserved

Page: 1 2 3 4 5

Related biology technology :

1. Cell Therapeutics, Inc. Reports Results of Annual Meeting of Shareholders
2. Orexigen® Therapeutics Reports Third Quarter Financial Results
3. Silence Therapeutics Provides Corporate and Development Update
4. Halozyme Therapeutics Reports Third Quarter 2011 Financial Results
5. Regado Biosciences, Inc. Presents Positive Efficacy and Safety Substudy Data from the Phase 2b RADAR Trial for the REG1 Anticoagulation System at the Transcatheter Cardiovascular Therapeutics (TCT) Symposium 2011
6. Karyopharm Therapeutics Closes $10 Million Series A2 Financing to Expand Planned Phase 1 Program of Oral Selective Inhibitors of Nuclear Export (SINE) for Cancer
7. Halozyme Therapeutics Announces Data From Two Phase 1 Studies of PEGPH20 Demonstrating Targeting of Hyaluronan in Tumor Stroma
8. United Therapeutics Corporation Reports Third Quarter 2011 Financial Results
9. Amsterdam Molecular Therapeutics Provides Operations Update & Strategic Review of Pipeline
10. Cell Therapeutics, Inc. (CTI) Reports Third Quarter Financial Results and Milestones
11. DLVR Therapeutics Inc. Raises Additional Capital Adding MaRS Innovation to Investor Base
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:10/30/2014)... 2014 Whitehouse Laboratories has formally announced ... Testing and Package Test Capacity. Responding to growing demands ... dramatic increase in environmental chamber storage space that will ... aging samples to be securely held on site at ... expenditure has already taken place with the recent completion ...
(Date:10/30/2014)... Calif. , Oct. 30, 2014 Isis Pharmaceuticals, ... therapeutics, today announced that management will present a company overview ... at 8:30 a.m. ET in Boston, MA. ... be available on the "Investors & Media" section of the ... on the Isis website within 48 hours and will be ...
(Date:10/30/2014)... challenges in the development of quantum technologies has been ... paper published today (28 October) in Nature Communications ... make a new type of flexibly designed microscopic trap ... sensors and specialised superfast computers, often depend on harnessing ... trapping these tiny particles are hugely problematic because of ...
(Date:10/27/2014)... The new research report, “Gas Insulated Switchgear (GIS) ... & Secondary), and End-User (Transmission & Distribution, Manufacturing ... - Trends and Forecasts to 2019”, defines and ... of the market size. , Browse more than ... through 146 Pages and in-depth TOC on “Gas ...
Breaking Biology Technology:Whitehouse Labs Announces Major Capital Investment in Stability and Storage Testing Capacity 2Whitehouse Labs Announces Major Capital Investment in Stability and Storage Testing Capacity 3Isis Pharmaceuticals to Present at the Nomura Biotechnology Conference 2Gas Insulated Switchgear Market worth $21,951.9 Million by 2019 - New Report by MarketsandMarkets 2Gas Insulated Switchgear Market worth $21,951.9 Million by 2019 - New Report by MarketsandMarkets 3Gas Insulated Switchgear Market worth $21,951.9 Million by 2019 - New Report by MarketsandMarkets 4
... Oct. 10 /Xinhua-PRNewswire-FirstCall/ -- Pharmaxis,(ASX: PXS; Nasdaq: PXSL) ... a placement to Australian, U.S., Asian and European ... balance,sheet as Pharmaxis continues with a series of ... of its manufacturing operation in,Sydney. Pharmaxis will ...
... October 10 The National,Institutes of Allergy and ... with Bavarian Nordic to include the initiation of,a ... investigational,smallpox vaccine, in persons diagnosed with atopic dermatitis. ... 2010 and has a value of,US$15 million, with ...
... OPK ),today announced that it has acquired exclusive ... compound with potential utility,in the treatment of dry eye. ... can disrupt the lives,of those afflicted. It can cause ... Sam Reich, Executive Vice President,of Ophthalmologics at OPKO. "There ...
Cached Biology Technology:Pharmaxis Announces Placement of $50 Million and Share Purchase Plan 2Government Expands Trial With IMVAMUNE(R) Smallpox Vaccine in Persons With Atopic Dermatitis/Eczema 2Government Expands Trial With IMVAMUNE(R) Smallpox Vaccine in Persons With Atopic Dermatitis/Eczema 3OPKO Health Acquires Rights to Clinical Stage Compound for Dry Eye 2OPKO Health Acquires Rights to Clinical Stage Compound for Dry Eye 3
(Date:10/30/2014)... 30 October 2014 Biological membranes are mainly composed ... adsorption of solution ions onto lipid membranes helps ... new study provides a quantitative description of the ... Joanna Kotyńska and Zbigniew Figaszewski from the University ... study describing these findings, just published in ...
(Date:10/29/2014)... OR) New research presented at the Society ... Houston, TX showed for the first time that ... women using a readily available nutritional supplement, AHCC. ... Dr. Judith A. Smith, Pharm.D., associate professor in ... at The University of Texas Health Science Center ...
(Date:10/29/2014)... the safety of nanoparticles is all the rage. Thousands ... examining the question of whether titanium dioxide nanoparticles from ... the body, whether carbon nanotubes from electronic products are ... be or whether nanoparticles in food can get into ... interest is great, research funds are flowing – and ...
Breaking Biology News(10 mins):Ion adsorption matter in biology 2HPV infections in women eradicated by AHCC, Japanese mushroom extract 2Nanosafety research: The quest for the gold standard 2Nanosafety research: The quest for the gold standard 3
... Scientists and engineers must join together in a major new ... crisis in providing Earth,s people with clean water that looms ... comment article in the current edition of Chemical & ... Society (ACS), the world,s largest scientific society. Bassam Z. ...
... of potential environmental and human health effects from disposal ... led scientists to recommend stronger government policies to encourage ... That,s the conclusion of a new paper in the ... Oladele A. Ogunseitan and colleagues point out that Li-ion ...
... life scientists provide important new details on how climate change ... 21 in the Journal of Animal Ecology . This ... informing policymakers of how species are likely to be impacted ... recognition among biologists that climate change is affecting how species ...
Cached Biology News:UCLA life scientists present new insights on climate change and species interactions 2UCLA life scientists present new insights on climate change and species interactions 3UCLA life scientists present new insights on climate change and species interactions 4UCLA life scientists present new insights on climate change and species interactions 5
... BioNumerics is the universal bioinformatics software that ... data. The unique modular design of BioNumerics ... virtually any type of data employed for ... microarrays, DNA fingerprints, 2-D protein gels, HPLC, ...
... early 80s Biosearch Technologies has been ... tools to accelerate the discovery and ... need dual-labeled FRET probes and primers ... for microarray applications, Biosearch can meet ...
UNIVERSAL SCORECARD DNA, 1 EA. * Category: Reagents/Consumables....
mitochondrial proteins (human heart) for 2-D gel electrophoresis *5 mg/mL*...
Biology Products: